Drug Formulary Review Archives – July 1, 2003
July 1, 2003
View Issues
-
Report recommends earlier treatment of hypertension
New clinical practice guidelines for the prevention, detection, and treatment of high blood pressure recommend earlier and more aggressive intervention for control of the disease. -
Key facts from the JNC 7 report
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) provides new clinical guidelines for hypertension prevention and management. -
Dementia rates increase for older women on HRT
Older women taking combination hormone therapy had dementia twice as often as women not taking the therapy, according to a recently published study. -
Beware of counterfeit atorvastatin calcium
The U.S. Food and Drug Administration (FDA) is warning pharmacists and consumers to beware of counterfeit atorvastatin calcium (Lipitor). -
Injunction lifted against discount drug program
The U.S. Supreme Court has ruled that Maine can continue with its efforts to implement its Maine Rx program, which was designed primarily to provide discounted prescription drugs to Maines uninsured residents. -
Status of postmarketing studies to be posted
The FDA has announced two measures to inform the public about the status of manufacturers commitments to carry out further clinical studies following the FDAs approval of certain drugs and biological products. -
FDA, NCI plan to streamline cancer drug development
The U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have recently announced that they will share knowledge and resources to facilitate the development of new cancer drugs and speed their delivery to patients. -
Drug Criteria & Outcomes: Urokinase (Abbokinase) formulary evaluation
Due to manufacturing problems, the U.S. Food and Drug Administration (FDA) took urokinase (Abbokinase) off the market in December 1998. During inspection of the manufacturing facility in October and November of 1998, urokinase production was found to differ from Good Manufacturing Practice regulations. -
Drug Criteria & Outcomes: In the Pipeline
In the Pipeline